Regencell Bioscience Holdings Ltd. (RGC)
5.02
+0.24
(+5.02%)
USD |
NASDAQ |
Jul 17, 16:00
5.05
+0.03
(+0.60%)
After-Hours: 20:00
Price Chart
Chart unavailable
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.482B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -66.22% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong. |
| URL | http://www.regencellbioscience.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Oct. 28, 2026 (est.) |
| Last Earnings Release | Jun. 15, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong. |
| URL | http://www.regencellbioscience.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Oct. 28, 2026 (est.) |
| Last Earnings Release | Jun. 15, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |